Moreover, ANKDD1A is highly frequently methylated in glioma, and the tumor-specific methylation of ANKDD1A indicated that it could be used as a potential epigenetic biomarker and possible therapeutic target. The gene discussed is ANKDD1A; the disease is neoplasm.